365 related articles for article (PubMed ID: 15552785)
1. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
2. Value of FDG-PET in the management of non-small cell lung cancer.
Stroobants S; Verschakelen J; Vansteenkiste J
Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
[TBL] [Abstract][Full Text] [Related]
3. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
4. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET in staging lung cancer: how does it change the algorithm?
Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
Truong MT; Viswanathan C; Erasmus JJ
J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
Erasmus JJ; Rohren E; Swisher SG
Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
[TBL] [Abstract][Full Text] [Related]
8. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
9. FDG PET: advantages for staging the mediastinum?
Franzius C
Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG-PET in the diagnosis and management of lung cancer.
Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP
Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660
[TBL] [Abstract][Full Text] [Related]
11. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Vansteenkiste JF; Stroobants SG
Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
[TBL] [Abstract][Full Text] [Related]
12. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography imaging in nonsmall-cell lung cancer.
Erasmus JJ; Macapinlac HA; Swisher SG
Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
[TBL] [Abstract][Full Text] [Related]
14. [Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
Colavolpe C; Bonardel G; Guedj E; Cammilleri S; Mundler O; Barlesi F
Rev Mal Respir; 2012 Feb; 29(2):149-60. PubMed ID: 22405110
[TBL] [Abstract][Full Text] [Related]
15. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
16. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
17. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
[TBL] [Abstract][Full Text] [Related]
19. The role of FDG-PET in the management of non-small cell lung carcinoma.
Ho Shon IA; Maisey MN
Ann Acad Med Singap; 2004 Mar; 33(2):166-74. PubMed ID: 15098629
[TBL] [Abstract][Full Text] [Related]
20. Response to radiation.
Rosenzweig KE; Fox JL; Giraud P
Semin Radiat Oncol; 2004 Oct; 14(4):322-5. PubMed ID: 15558507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
